Salbutamol Nebulisation Dose and Dilution Guide

Generic name: Salbutamol (albuterol) nebuliser solution | Last reviewed: 29 September 2026

Key points

Nebulised salbutamol treats bronchospasm but does not replace anti-inflammatory asthma control.
Children should use home nebulisers only under a specialist-directed plan.
Verify whether the product is unit-dose or concentrated solution before measuring.
Tachycardia, tremor, hypokalaemia and lactic acidosis are important dose-related risks.

Indications and clinical role

Short-acting beta-2 agonist for relief of reversible bronchospasm in asthma and COPD. Repeated or continuous nebulisation belongs in monitored acute-care protocols.

Adult dosing

Typical intermittent nebulised dose: 2.5–5 mg, up to four times daily. Higher cumulative dosing may be used only under strict hospital supervision and protocol.

Verified paediatric dosing

Age 12 years and above: adult dosing. Age 4–11 years: 2.5–5 mg up to four times daily. Some authorised concentrated-solution labels describe 2.5 mg as the starting dose in children under 12, diluted to the nebuliser’s required fill volume. Under-4 dosing and repeated acute regimens require specialist/local protocol.

Marketed formulations and strengths

India examples include unit-dose respules commonly labelled 2.5 mg/2.5 mL or 5 mg/2.5 mL, and some concentrated solutions. Exact strengths, excipients and pack sizes vary by manufacturer.

Educational calculation example

Using a 1 mg/mL solution, a prescribed 2.5 mg dose requires 2.5 mL. If the nebuliser requires a 4 mL fill volume, add 1.5 mL sterile 0.9% sodium chloride—only if the product label and device instructions permit dilution.

Preparation and dilution

Confirm strength first. Open a unit-dose ampoule immediately before use. Transfer the prescribed amount to the nebuliser chamber using aseptic technique. Do not save an opened single-dose container. Concentrated products may require sterile normal saline to the device fill volume.

Route, administration and rate

For inhalation through a compatible jet nebuliser with mouthpiece or well-fitted mask. Administer until nebulisation stops, commonly over several minutes depending on device and flow. Ensure ventilation because fugitive aerosol can expose carers.

Storage, stability and compatibility

Protect unopened units as specified by the manufacturer, commonly from light and excessive heat. Use promptly after opening. Do not mix with other nebulised medicines unless compatibility and sequence are supported by the product label or institutional protocol.

Renal and hepatic considerations

No routine inhaled-dose adjustment is generally specified, but systemic exposure and electrolyte effects warrant caution in frail patients and during high-dose/repeated therapy.

Pregnancy and lactation

Use when clinically indicated after benefit–risk assessment. Poorly controlled asthma itself carries maternal and fetal risk. Inhaled use generally produces lower systemic exposure than oral/parenteral therapy.

Contraindications and major interactions

Hypersensitivity to ingredients. Non-selective beta-blockers may antagonise bronchodilation and provoke bronchospasm. Other sympathomimetics, diuretics, corticosteroids and xanthines may increase cardiovascular or hypokalaemia risk.

Monitoring

Symptoms, respiratory rate, work of breathing, oxygen saturation, peak flow where appropriate, heart rate, tremor and response. Check potassium and lactate during severe attacks or repeated/high-dose therapy when clinically indicated.

Adverse effects

Common: tremor, palpitations, tachycardia, headache and muscle cramps. Serious: paradoxical bronchospasm, arrhythmia, significant hypokalaemia, myocardial ischaemia in susceptible patients and lactic acidosis with excessive dosing.

Medication-error and concentration warnings

Never assume all respules contain the same mg/mL. Confusing total mg with concentration or using concentrated solution undiluted can cause overdose. Worsening symptoms or increasing reliever use requires urgent clinical reassessment.

India availability caveat

Asthalin is one representative Cipla brand; multiple Indian brands and strengths exist. This is not an endorsement. Always verify the actual product label, concentration and local hospital protocol.

Official/authoritative sources

Representative product-image note: Any market pack shown is an identification example only, not an endorsement.

Educational disclaimer: This article is for professional education and public information. It does not replace individual diagnosis, prescription, emergency assessment or local institutional protocol.